Ceftazidime Injectable (Iv/Im) Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV/IM)

Available Strengths: 1 g, 2 g, 2.5 g, 3 g, 4 g per vial

Reference Brands: Fortaz, Tazicef(US& EU)

Category: Antibiotics

Ceftazidime inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, leading to bacterial lysis. It is effective against Pseudomonas aeruginosa and other gram-negative bacteria. Benefits include rapid, potent action in severe infections, broad-spectrum activity, and utility in hospital settings for pneumonia, sepsis, and complicated infections. Ceftazidime Injectable (IV/IM) is available in Injectable (IV/IM) and strengths such as 1 g, 2 g, 2.5 g, 3 g, 4 g per vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ceftazidime Injectable (IV/IM) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Ceftazidime Injectable (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Ceftazidime injectable is approved in the EU and US for treating severe bacterial infections, including pneumonia, sepsis, and complicated urinary tract infections. In the EU, brands like Fortaz are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality standards. In the US, FDA approval relies on extensive clinical data and manufacturing compliance, with generic formulations available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans, for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers and compliance, visit PharmaTradz. We support seamless market access, ensuring adherence to European and American standards for safe, effective antibacterial therapy.